{"id":"neulasta-pegfilgrastim","safety":{"commonSideEffects":[{"rate":"25–30","effect":"Bone pain"},{"rate":"10–15","effect":"Fatigue"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Nausea"},{"rate":"<1","effect":"Splenic rupture (rare)"},{"rate":"<1","effect":"Acute respiratory distress syndrome (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic cells. By activating these receptors, it promotes the growth, differentiation, and activation of neutrophil precursors, leading to increased production and release of mature neutrophils into the bloodstream. The pegylation extends its half-life, allowing for less frequent dosing compared to filgrastim.","oneSentence":"Pegfilgrastim stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow to increase circulating neutrophil counts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:03.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"},{"name":"Severe chronic neutropenia (SCN)"},{"name":"Mobilization of peripheral blood progenitor cells for autologous transplantation"}]},"trialDetails":[{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":"High Grade Glioma, CNS Tumor","enrollment":52},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT06711523","phase":"PHASE3","title":"Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2025-01-09","conditions":"Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female","enrollment":250},{"nctId":"NCT02369458","phase":"PHASE2","title":"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-04-14","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck","enrollment":48},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT04023669","phase":"PHASE1","title":"Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-08","conditions":"Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory","enrollment":21},{"nctId":"NCT03433560","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2018-01-18","conditions":"Breast Cancer Female, Breast Neoplasm Female","enrollment":1300},{"nctId":"NCT06168188","phase":"EARLY_PHASE1","title":"The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-07-24","conditions":"Traumatic Optic Neuropathy","enrollment":20},{"nctId":"NCT02649673","phase":"PHASE1","title":"LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-03-23","conditions":"Small Cell Lung Cancer, Ovarian Cancer","enrollment":34},{"nctId":"NCT06116734","phase":"PHASE3","title":"Lapelga vs Gastrofil","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-11-01","conditions":"Multiple Myeloma, Lymphoma, Engagement, Patient","enrollment":74},{"nctId":"NCT03252431","phase":"PHASE3","title":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2018-04-12","conditions":"Breast Cancer, Neutropenia","enrollment":393},{"nctId":"NCT02578732","phase":"PHASE2","title":"FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial","status":"COMPLETED","sponsor":"Brown University","startDate":"2016-07-12","conditions":"Locally Advanced Pancreatic Cancer, Pancreatic Cancer","enrollment":28},{"nctId":"NCT04661852","phase":"PHASE1","title":"Cabozantinib With Topotecan-Cyclophosphamide","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-23","conditions":"Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma","enrollment":12},{"nctId":"NCT02044276","phase":"PHASE3","title":"A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-03-31","conditions":"Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia","enrollment":101},{"nctId":"NCT00887536","phase":"PHASE3","title":"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1613},{"nctId":"NCT01724866","phase":"PHASE2","title":"Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2013-03-25","conditions":"Neutropenia","enrollment":148},{"nctId":"NCT02953340","phase":"PHASE3","title":"SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2017-05-10","conditions":"Neutropenia, Breast Cancer","enrollment":237},{"nctId":"NCT02643420","phase":"PHASE3","title":"SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2016-01-19","conditions":"Neutropenia, Breast Cancer","enrollment":406},{"nctId":"NCT02479646","phase":"PHASE1","title":"Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-09","conditions":"Healthy Volunteers","enrollment":218},{"nctId":"NCT02467868","phase":"PHASE3","title":"Efficacy and Safety Study With MYL-1401H and Neulasta","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-03","conditions":"Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia","enrollment":193},{"nctId":"NCT02776059","phase":"PHASE2","title":"Pegfilgrastim in Patients With Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2017-01-21","conditions":"Alcoholic Hepatitis","enrollment":34},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT01840579","phase":"PHASE1","title":"Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-26","conditions":"Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT03511378","phase":"PHASE4","title":"Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2018-03-06","conditions":"Breast Cancer","enrollment":138},{"nctId":"NCT02392793","phase":"PHASE1","title":"Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-03-25","conditions":"Childhood Solid Tumors","enrollment":43},{"nctId":"NCT04651036","phase":"PHASE1","title":"A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-06","conditions":"Healthy","enrollment":300},{"nctId":"NCT02181218","phase":"PHASE1","title":"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-02-04","conditions":"Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease","enrollment":24},{"nctId":"NCT04460079","phase":"","title":"Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-03-29","conditions":"Chemotherapy-induced Neutropenia","enrollment":654},{"nctId":"NCT03619993","phase":"NA","title":"Patient Preference for Pegfilgrastim (Neulasta®) Application Forms","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2018-06-25","conditions":"Non Hodgkin Lymphoma, Breast Cancer","enrollment":404},{"nctId":"NCT00394251","phase":"PHASE2","title":"Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-08-01","conditions":"Breast Cancer","enrollment":197},{"nctId":"NCT04015232","phase":"PHASE1","title":"Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.","status":"COMPLETED","sponsor":"Intas Pharmaceuticals, Ltd.","startDate":"2018-02-26","conditions":"Immunogenicity, Healthy Volunteers","enrollment":200},{"nctId":"NCT01106157","phase":"PHASE1, PHASE2","title":"Reversing Type 1 Diabetes After it is Established","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT03251339","phase":"PHASE1","title":"Safety and Immunogenicity of MSB11455 in Healthy Participants","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-08-21","conditions":"Healthy","enrollment":336},{"nctId":"NCT00254410","phase":"PHASE2","title":"FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-03-14","conditions":"Chronic Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03559387","phase":"PHASE2","title":"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","status":"TERMINATED","sponsor":"Prolong Pharmaceuticals","startDate":"2017-08-03","conditions":"Chemotherapy-induced Neutropenia","enrollment":9},{"nctId":"NCT00094809","phase":"PHASE2","title":"Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-02-01","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":252},{"nctId":"NCT01648322","phase":"PHASE2","title":"Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2012-06","conditions":"Breast Cancer, Neutropenia","enrollment":232},{"nctId":"NCT00569673","phase":"PHASE2","title":"Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2008-03","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":71},{"nctId":"NCT03202927","phase":"PHASE1","title":"Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-03-25","conditions":"Healthy Volunteers","enrollment":102},{"nctId":"NCT03206229","phase":"PHASE1","title":"Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-02-13","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT01692691","phase":"PHASE2","title":"Dacarbazine and Carmustine in Metastatic Melanoma","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2012-08","conditions":"Melanoma Metastatic","enrollment":1},{"nctId":"NCT01712009","phase":"PHASE2","title":"NOLAN: Naproxen or Loratadine and Neulasta","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-01","conditions":"Bone Pain in Stage I - III Breast Cancer","enrollment":600},{"nctId":"NCT02983097","phase":"PHASE1, PHASE2","title":"Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2010-11","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant","enrollment":34},{"nctId":"NCT03404752","phase":"PHASE3","title":"Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2015-08","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00911170","phase":"PHASE3","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-03","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":847},{"nctId":"NCT03146988","phase":"PHASE1","title":"Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2017-04-10","conditions":"Bioequivalence","enrollment":150},{"nctId":"NCT02629562","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects","status":"COMPLETED","sponsor":"Cinfa Biotech","startDate":"2015-11","conditions":"Clinical Pharmacology","enrollment":172},{"nctId":"NCT02768714","phase":"PHASE3","title":"Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2018-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01516736","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-03","conditions":"Chemotherapy-induced Neutropenia, Breast Cancer","enrollment":308},{"nctId":"NCT01735175","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-06","conditions":"Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia","enrollment":316},{"nctId":"NCT01594918","phase":"PHASE1","title":"Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Rahul Aggarwal","startDate":"2012-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":25},{"nctId":"NCT02098109","phase":"PHASE2","title":"Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-08-20","conditions":"Multiple Myeloma, Lymphoma, Non-Hodgkin","enrollment":100},{"nctId":"NCT00816595","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-02","conditions":"Leukemia, Lymphoma","enrollment":68},{"nctId":"NCT02912377","phase":"PHASE1","title":"Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects","status":"COMPLETED","sponsor":"Cinfa Biotech","startDate":"2016-09","conditions":"Healthy Volunteers","enrollment":96},{"nctId":"NCT02589301","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2015-11","conditions":"Neutropenia, Healthy","enrollment":100},{"nctId":"NCT01541072","phase":"NA","title":"Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation","status":"TERMINATED","sponsor":"Centre Leon Berard","startDate":"2012-02","conditions":"Non Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT01701076","phase":"PHASE2","title":"Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2012-03","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02469116","phase":"PHASE2","title":"Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2006-01","conditions":"Ovarian Cancer","enrollment":18},{"nctId":"NCT02650973","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2016-02","conditions":"Healthy","enrollment":122},{"nctId":"NCT00503984","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Miami","startDate":"2007-05","conditions":"Prostate Cancer, Pain","enrollment":22},{"nctId":"NCT01859637","phase":"PHASE4","title":"Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia","status":"TERMINATED","sponsor":"Sandoz","startDate":"2011-07","conditions":"Severe Chronic Neutropenia","enrollment":6},{"nctId":"NCT02418104","phase":"PHASE1","title":"Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-05","conditions":"Immunity, Humoral","enrollment":303},{"nctId":"NCT00588094","phase":"PHASE2","title":"Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-10","conditions":"Lymphoma, B-cell Non-Hodgkin's Lymphoma","enrollment":20},{"nctId":"NCT02385851","phase":"PHASE1","title":"Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-02","conditions":"Bioequivalence","enrollment":116},{"nctId":"NCT01519700","phase":"PHASE3","title":"Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim","status":"COMPLETED","sponsor":"Sandoz","startDate":"2011-12","conditions":"Chemotherapy Associated Neutropenia, Breast Cancer","enrollment":218},{"nctId":"NCT00662519","phase":"PHASE1","title":"Neulasta in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-04","conditions":"Type 1 Diabetes","enrollment":21},{"nctId":"NCT00240097","phase":"PHASE2","title":"Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2005-06","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00115193","phase":"PHASE2","title":"Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-02","conditions":"Non-Hodgkin's Lymphoma","enrollment":77},{"nctId":"NCT00777673","phase":"PHASE2","title":"Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.","status":"UNKNOWN","sponsor":"University of Tennessee Cancer Institute","startDate":"2008-10","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00007904","phase":"PHASE2","title":"Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-07","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT00503750","phase":"PHASE2","title":"Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-04","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT00969826","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-09","conditions":"Healthy","enrollment":38},{"nctId":"NCT00125723","phase":"PHASE4","title":"FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-05","conditions":"Neutropenia","enrollment":2252},{"nctId":"NCT00794261","phase":"PHASE2","title":"Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2008-09","conditions":"Lymphoma, Myeloma","enrollment":150},{"nctId":"NCT00115206","phase":"PHASE4","title":"Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07","conditions":"Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00094822","phase":"","title":"Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-07","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT00113789","phase":"PHASE2","title":"Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-10","conditions":"Ovarian Cancer","enrollment":21},{"nctId":"NCT00114764","phase":"PHASE2","title":"Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-03","conditions":"Myeloid Leukemia","enrollment":84},{"nctId":"NCT00115414","phase":"PHASE2","title":"Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Breast Cancer, Fever, Neutropenia","enrollment":""},{"nctId":"NCT00117910","phase":"PHASE3","title":"Treatment for Elderly Patients With High Risk Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-10","conditions":"Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Neulasta® (pegfilgrastim)","genericName":"Neulasta® (pegfilgrastim)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegfilgrastim stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Severe chronic neutropenia (SCN), Mobilization of peripheral blood progenitor cells for autologous transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}